ThyroidPrint® - A New Diagnostic Test

Join this Lunch and Learn with Leonie Wheeldon, Consultant Biomedical Scientist on ThyroidPrint® 

A new diagnostic test called ThyroidPrint® is being trialled across eight NHS Trusts in England to improve the care pathway for indeterminate thyroid nodules.

🔍 The Challenge

Thyroid nodules are common, and while most are benign, around 25% are classified as indeterminate after Fine Needle Aspiration (FNA) cytology. Currently a definite diagnosis is provided by surgery to remove half or all of the Thyroid. The majority will be benign, meaning that most patients are having unnecessary invasive surgery.

Molecular profiling offers a powerful tool for risk stratification, but this is not available in the UK and is expensive, takes weeks for results and relies on significant expertise.

🧪 The Solution
The ThyroidPrint® molecular test performed on FNA samples provides a rapid, local, and cost-effective way to risk score indeterminate nodules within days, without the need for specialist expertise.

💡 Potential Impact
If successful, the test could:

• Reduce unnecessary surgeries for benign nodules
• Alleviate patient anxiety
• Lower NHS costs and surgical burden
• Significantly reduce the cancer pathway

Questions about this event?

Name: Hardeep Basan

Email: h.basan@nhs.net

Telephone: N/A.................